How Does 3SBio Company Work?

3SBio Bundle

Get Full Bundle:

	PESTLE	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

How Does 3SBio Operate?

3SBio Inc. is a leading biopharmaceutical company in China, demonstrating significant growth in 2024. The company reported RMB 9.108 billion in revenue, a 16.5% increase year-on-year, with net profit reaching approximately RMB 2.09 billion, up 34.9%.

With a strong focus on oncology, nephrology, and immunology, 3SBio is at the forefront of China's biopharmaceutical innovation. Its operational success is driven by a robust product pipeline and strategic market penetration.

How does 3SBio Company work?

The company's operational model centers on research, development, manufacturing, and commercialization of innovative biological products. A key driver of its revenue is the recombinant human thrombopoietin (rhTPO) product, TPIAO, which generated RMB 5.062 billion in sales in 2024, marking a 20.4% increase. This highlights the company's ability to successfully bring novel therapies to market and achieve substantial commercial success. Investors and industry observers can gain deeper insights into the company's market positioning and regulatory environment by reviewing the 3SBio PESTEL Analysis.

3SBio's core operations encompass the comprehensive research, development, manufacturing, and marketing of biopharmaceutical products. The company focuses on therapeutic areas like oncology, nephrology, and immunology, with a strong emphasis on recombinant protein products. This integrated approach allows 3SBio to bring innovative treatments from concept to market.

Core Therapeutic Areas

3SBio concentrates its efforts on key therapeutic areas including oncology, nephrology, and immunology. Its product portfolio is particularly strong in recombinant protein products, addressing critical patient needs in these fields.

Product Portfolio Highlights

Key products include TPIAO for thrombocytopenia, rhEPO products EPIAO and SEPO, Yisaipu for autoimmune diseases, Cipterbin for HER2-positive metastatic breast cancer, and Mandi for hair loss. These offerings represent significant advancements in their respective treatment categories.

Research and Development Pipeline

As of December 31, 2024, 3SBio maintained an active pipeline of 30 product candidates. A significant portion, 29, are being developed as innovative drugs in Mainland China, comprising 18 antibodies, 6 other biologic products, and 6 small molecule drugs.

Manufacturing and Distribution Network

With manufacturing facilities in Shenyang, Shanghai, Hangzhou, Shenzhen, China, and Como, Italy, 3SBio supports its global reach. Its extensive sales network served over 11,000 hospitals and medical institutions in Mainland China in 2024, with products also available in 20 other countries.

Value Proposition and Market Leadership

3SBio's unique value proposition is built on leading market positions for its core products and a strong commitment to innovation. This strategy drives significant customer benefits by providing high-quality therapies that address unmet medical needs and improve patient outcomes.

• TPIAO held a 66.6% market share in the treatment of thrombocytopenia in Mainland China in 2024.
• Its rhEPO products maintained a 42.0% market share in the same year.
• R&D expenditure increased by 70% in 2024, reaching approximately $150 million.
• This investment supports key projects, including an innovative drug for chronic kidney disease in Phase III trials.

The company's approach to 3SBio operations and its overall 3SBio business model are designed to foster continuous growth and impact in the biopharmaceutical industry. Understanding Revenue Streams & Business Model of 3SBio provides further insight into how 3SBio functions and its strategic direction.

3SBio SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

3SBio's primary revenue stream originates from the sales of its diverse biopharmaceutical products. In 2024, the company achieved a total revenue of approximately RMB 9.108 billion, marking a significant 16.5% increase compared to the previous year. This growth is largely attributed to its robust portfolio of market-leading drugs, which form the backbone of its monetization strategy.

TPIAO Sales Dominance

TPIAO, the world's sole commercial recombinant human thrombopoietin, generated RMB 5.062 billion in sales in 2024. This represents a 20.4% year-on-year growth and secures a substantial 66.6% market share in China for thrombocytopenia treatment.

Mandi's Market Leadership

The hair loss treatment Mandi achieved RMB 1.337 billion in sales in 2024, an 18.9% increase year-on-year. Mandi continues to hold a leading position within the Chinese minoxidil market.

EPIAO and SEPO Market Share

EPIAO and SEPO, both recombinant human erythropoietin products, maintained their dominant market positions. In 2024, the company held a 42.0% market share in Mainland China for rhEPO.

Yisaipu's Steady Growth

As the first TNF-α inhibitor introduced in Mainland China, Yisaipu demonstrated steady sales growth through proactive market expansion efforts.

Cipterbin's Rapid Advancement

Cipterbin exhibited strong sales performance, driven by increasing clinical recognition and extended patient treatment cycles. In the first half of 2024, sales for HER2-positive metastatic breast cancer reached RMB 162 million, a 48.9% year-on-year increase.

Strategic Partnerships for Monetization

Beyond direct product sales, the company leverages strategic partnerships and licensing agreements as key monetization strategies. These collaborations enhance revenue potential and expand market reach.

The company's business model is further strengthened by its ability to monetize its innovative pipeline through strategic collaborations. A prime example is the exclusive global licensing agreement with Pfizer for SSGJ-707, a bispecific antibody, announced in May 2025. This deal includes an upfront payment of $1.25 billion, potential milestone payments up to $4.8 billion, and tiered double-digit royalties on sales. This highlights the company's success in generating substantial revenue from its research and development efforts. Furthermore, in 2024, the company introduced Semaglutide Injection, Paclitaxel Oral Solution, Clifutinib, and Her-2 ADC through external partnerships, actively pursuing commercialization opportunities for its pipeline assets. Understanding these revenue streams is crucial for analyzing the Competitors Landscape of 3SBio and its overall market position.

Key Revenue Drivers and Monetization Strategies

3SBio's financial performance is underpinned by its successful product sales and strategic licensing agreements. The company's ability to secure significant upfront payments and future royalties demonstrates a robust monetization strategy for its innovative biopharmaceutical products.

• Primary revenue from biopharmaceutical product sales.
• Significant growth in total revenue, reaching RMB 9.108 billion in 2024.
• Flagship product TPIAO leads sales with RMB 5.062 billion in 2024.
• Strategic licensing deals, such as the Pfizer agreement for SSGJ-707, provide substantial upfront payments and future royalties.
• Introduction of new products via external partnerships in 2024 expands commercialization opportunities.
• Dominant market share in key therapeutic areas like thrombocytopenia and hair loss treatments.

3SBio PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

3SBio has marked significant progress in its operations, with 2024 being a notable year for product approvals and strategic partnerships. The company's commitment to innovation and market expansion underpins its functioning within the biotechnology sector.

Key Milestones in 2024

In 2024, 3SBio achieved commercial launch approval for three drugs, including eltrombopag for oral suspension. The company also submitted new drug applications for four products, such as long-acting erythropoietin (SSS06), and saw its anti-IL-17A mAb (608) for plaque psoriasis meet all efficacy endpoints in Phase III trials, with its new drug application accepted by the NMPA.

Product Portfolio Expansion

Further solidifying its market position, TPIAO received approval for treating primary immune thrombocytopenia in children and adolescents and was renewed on the 2024 National Reimbursement Drug List. The Mandi foam formulation also received approval for launch in January 2024.

Strategic Partnerships and Collaborations

3SBio strategically partnered with Haihe Biopharma in October 2024 to acquire commercialization rights for paclitaxel oral solution, Liporaxel, enhancing accessibility for cancer patients. Additionally, a 2024 collaboration with Hybio Pharmaceutical focused on the weight loss indication for semaglutide injection.

Competitive Advantages and Market Position

The company's competitive edge is built on strong brand recognition, evident in TPIAO's 66.6% market share in China for 2024 and its rhEPO products holding a 42.0% market share. This market dominance is supported by a robust R&D pipeline.

Technological Leadership and R&D Prowess

As of December 2024, 3SBio boasts 30 product candidates, with 29 being innovative drugs and 10 already in Phase III clinical trials, showcasing its commitment to drug discovery and development. This efficient R&D capability, combined with government support for biotechnology in China, strengthens its position.

• 3SBio operations are driven by a strong R&D pipeline with 30 product candidates as of December 2024.
• 29 of these candidates are innovative drugs, highlighting the company's focus on novel therapies.
• 10 candidates are in Phase III clinical trials, indicating advanced stages of product development.
• The company's global reach is expanding, with products sold in 20 countries in 2024 and five candidates having IND applications approved by the U.S. FDA, demonstrating its international strategy.

3SBio Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

3SBio holds a prominent position in China's biopharmaceutical sector, a market anticipated to reach USD 31,487.9 million by 2030. The company's flagship product, TPIAO, captured a substantial 66.6% market share for thrombocytopenia treatment in Mainland China as of 2024. Its recombinant human erythropoietin (rhEPO) products collectively hold a 42.0% market share, demonstrating strong customer loyalty and extensive distribution networks.

Industry Position

3SBio is a leader in the Chinese biopharmaceutical market, with its products sold in 20 countries in 2024. Its dominant market share in key therapeutic areas, including a 66.6% share for TPIAO in thrombocytopenia treatment, underscores its strong industry standing.

Key Products and Market Share

The company's flagship product, TPIAO, held a 66.6% market share in its segment in Mainland China in 2024. Additionally, its rhEPO products achieved a combined market share of 42.0%, highlighting its significant presence in these therapeutic areas.

Risks and Challenges

The biopharmaceutical industry presents several risks, including evolving regulatory landscapes in China, the potential impact of patent expirations, and the emergence of new competitors. Supply chain disruptions also pose a threat to manufacturing and distribution.

Future Outlook and Strategy

3SBio is focused on sustained revenue growth through innovation and strategic initiatives, particularly in hematology, oncology, and autoimmune diseases. The company is expanding its global reach and pipeline, with 30 product candidates as of December 2024.

Innovation and Collaboration

3SBio's future strategy involves leveraging both in-house R&D and external partnerships to accelerate innovative drug development. A significant example is the May 2025 licensing deal with Pfizer, valued at $1.25 billion upfront, for SSGJ-707, underscoring its commitment to global commercialization.

• Focus on hematology and oncology, nephrology, autoimmune diseases, hair health, and dermatology.
• Pipeline includes 30 product candidates, with 10 in Phase III clinical trials as of December 2024.
• Emphasis on in-house R&D and strategic external partnerships.
• Global perspective to accelerate innovative drug development and commercialization.
• The Growth Strategy of 3SBio highlights its approach to market expansion and pipeline monetization.

3SBio Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔